First Patient Treated in Trial of prGCD Treatment of Gaucher Disease

Protalix BioTherapeutics has treated the first patient in its Phase III clinical trial of the company’s lead product candidate, prGCD, a proprietary plant cell expressed recombinant form of human Glucocerebrosidase for the treatment of Gaucher disease, a lysosomal storage disorder in humans, the company announced.

The Phase III clinical trial will take place in centers in the U.S., Israel and other locations worldwide. The trial design consists of 30 male and female patients with Gaucher disease in a randomized, double-blind, dose ranging study, with two parallel groups.